37
Participants
Start Date
February 28, 2009
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
Sorafenib and Dacarbazine
"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
Memorial Sloan-Kettering Cancer Center, New York
Collaborators (1)
Bayer
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER